Posted by Michael Wonder on 01 Feb 2022
Novavax submits request to the U.S. FDA for emergency use authorisation of COVID-19 Vaccine
31 January 2022 - NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains.
Novavax today announced that it has submitted a request to the U.S FDA for emergency use authorisation for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunisation of individuals 18 year of age and older against SARS-CoV-2.
